Your browser doesn't support javascript.
loading
Delivery of rapamycin by biomimetic peptide nanoparticles targeting oxidized low-density lipoprotein in atherosclerotic plaques.
Wang, Anqi; Yue, Kai; Zhong, Weishen; Zhang, Genpei; Wang, Lei; Zhang, Hua; Zhang, Xinxin.
Afiliación
  • Wang A; School of Energy and Environmental Engineering, University of Science and Technology Beijing, Beijing 100083, China. yuekai@ustb.edu.cn.
  • Yue K; School of Energy and Environmental Engineering, University of Science and Technology Beijing, Beijing 100083, China. yuekai@ustb.edu.cn.
  • Zhong W; Shunde Graduate School of University of Science and Technology Beijing, Shunde, Guangdong Province, 528399, China.
  • Zhang G; School of Energy and Environmental Engineering, University of Science and Technology Beijing, Beijing 100083, China. yuekai@ustb.edu.cn.
  • Wang L; School of Energy and Environmental Engineering, University of Science and Technology Beijing, Beijing 100083, China. yuekai@ustb.edu.cn.
  • Zhang H; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.
  • Zhang X; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Biomater Sci ; 12(16): 4181-4193, 2024 Aug 06.
Article en En | MEDLINE | ID: mdl-38979569
ABSTRACT
Drug delivery systems based on biomimetic peptide nanoparticles are steadily gaining prominence in the treatment of diverse medical conditions. This study focused on the development of peptides that depend on ligand-receptor interactions to load rapamycin (RAPA). Furthermore, a multifunctional peptide was engineered to target oxidized low-density lipoprotein (oxLDL) within atherosclerotic plaques, facilitating the localized delivery of RAPA. The interactions between peptides and RAPA/oxLDL were analyzed by simulations and experimental approaches. Results show that the main amino acid residues on the mammalian target of rapamycin that bind to RAPA are constructed as peptides (P1 and P2), which have specific interactions with RAPA and can effectively improve the loading efficiency of RAPA. The encapsulation and drug loading efficiencies of P1/P2 were 68.0/47.9% and 48.3/36.5%, respectively. In addition, the interaction force of the multifunctional peptide (P3) and oxLDL surpassed that of their interaction with human umbilical vein endothelial cells by a factor of 3.6, conclusively establishing the specific targeting of oxLDL by these nanoparticles. The encapsulation and drug loading efficiencies of P3 for RAPA were determined to be 60.2% and 41.5%. P3 can effectively load RAPA and target oxLDL within the plaque, suggesting that P3 has potential as a therapeutic agent for atherosclerotic disease.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Sirolimus / Nanopartículas / Placa Aterosclerótica / Células Endoteliales de la Vena Umbilical Humana / Lipoproteínas LDL Límite: Humans Idioma: En Revista: Biomater Sci Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Sirolimus / Nanopartículas / Placa Aterosclerótica / Células Endoteliales de la Vena Umbilical Humana / Lipoproteínas LDL Límite: Humans Idioma: En Revista: Biomater Sci Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido